Abstract
Dhiraj Mishra, Marcelo Calderón, Ana Beloqui, Alejandro Sosnik
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
10.1056/nejmoa043330 · 2005
The 2021 WHO classification of tumors of the central nervous system: a summary
10.1093/neuonc/noab106 · 2021
Diagnosis and management of glioblastoma: a comprehensive perspective
10.3390/jpm11040258 · 2021
Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma
10.1016/j.ijrobp.2011.06.1992 · 2012
Nordic clinical brain tumour study group (NCBTSG), temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the nordic randomised, phase 3 trial
10.1016/s1470-2045(12)70265-6 · 2012
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol
10.1186/s12885-019-5413-y · 2019
MGMT gene silencing and benefit from temozolomide in glioblastoma
10.1056/nejmoa043331 · 2005
Emerging treatment strategies for glioblastoma multiforme
10.15252/emmm.201302627 · 2014
Management of glioblastoma: state of the art and future directions
2020
Breaking barriers for glioblastoma with a path to enhanced drug delivery
10.1038/s41467-023-41694-9 · 2023
Advances in glioblastoma therapy: an update on current approaches
10.3390/brainsci13111536 · 2023
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
10.1038/s41571-020-00447-z · 2021
Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies
10.1038/s41388-017-0045-7 · 2018
Targeting angiogenesis in gliomas: potential role of phytochemicals
10.1016/j.jff.2022.105192 · 2022
The promise of DNA damage response inhibitors for the treatment of glioblastoma, neuro-oncol
2021
How do phosphodiesterase-5 inhibitors affect cancer? A focus on glioblastoma multiforme
10.1007/s43440-021-00349-6 · 2022
A novel approach to glioblastoma multiforme treatment using modulation of key pathways by naturally occurring small molecules
10.1007/s10787-025-01666-5 · 2025
Defining the role of mTOR in cancer
10.1016/j.ccr.2007.05.008 · 2007
Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance
2010
Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation
10.1073/pnas.83.11.3825 · 1986
Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab
10.4161/cbt.24342 · 2013
Cetuximab-conjugated magnetic poly(Lactic-co-glycolic acid) nanoparticles for dual-targeted delivery of Irinotecan in glioma treatment
10.3390/ma16165526 · 2023
The blood-brain barrier: structure, regulation, and drug delivery
10.1038/s41392-023-01481-w · 2023
Microphysiological systems for recapitulating physiology and function of blood-brain barrier
10.1016/j.biomaterials.2019.119732 · 2020
Lipid based nanoparticles: current strategies for brain tumor targeting
10.2174/2405461504666190510121911 · 2019
Strategies facilitating the permeation of nanoparticles through blood-brain barrier: an insight towards the development of brain-targeted drug delivery system
2023
Polymer-based nanocarriers to transport therapeutic biomacromolecules across the blood-brain barrier
10.1016/j.actbio.2025.02.065 · 2025
Strategies for delivering therapeutics across the blood-brain barrier
10.1038/s41573-021-00139-y · 2021
The blood-brain barrier: physiology and strategies for drug delivery
10.1016/j.addr.2019.11.009 · 2020
Nanoparticles mediated the diagnosis and therapy of glioblastoma: bypass or cross the blood-brain barrier
2023
Functionalized nanoparticles crossing the brain–blood barrier to target glioma cells
10.7717/peerj.15571 · 2023
RGD-based self-assembling nanodrugs for improved tumor therapy
2024
Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation
10.1186/s12943-023-01865-0 · 2023
Engineering precision nanoparticles for drug delivery
10.1038/s41573-020-0090-8 · 2021
Functionalized nanomaterials capable of crossing the blood–brain barrier
10.1021/acsnano.3c10674 · 2024
Emerging blood–brain- barrier-crossing nanotechnology for brain cancer theranostics
10.1039/c8cs00805a · 2019
Nanoparticle diagnostics and theranostics in the clinic
2022
All-aqueous electrosprayed emulsion for templated fabrication of cytocompatible microcapsules
10.1021/acsami.5b02708 · 2015
Microfluidic generation of aqueous two-phase-system (ATPS) droplets by oil-droplet choppers
10.1039/c7lc00696a · 2017
Advances in nanoparticle synthesis assisted by microfluidics
10.1039/d5lc00194c · 2025
Influence of glioma cells on a new co-culture in vitro blood–brain barrier model for characterization and validation of permeability
10.1016/j.ijpharm.2015.05.027 · doi-reference
Establishment and validation of a new Co-Culture for the evaluation of the permeability through the blood–brain barrier in patients with glioblastoma
10.3390/pharmaceutics15051431 · doi-reference
Enhanced cytotoxic activity of cetuximab in EGFR-positive lung cancer by conjugating with gold nanoparticles
10.1038/srep07490 · doi-reference
Nanoconjugation modulates the trafficking and mechanism of antibody induced receptor endocytosis
10.1073/pnas.1006507107 · doi-reference
Microfluidic-assisted preparation of RGD-decorated nanoparticles: exploring integrin-facilitated uptake in cancer cell lines
10.1038/s41598-020-71396-x · doi-reference
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
10.1016/j.ccr.2005.03.003 · doi-reference
In vitro responsiveness of glioma cell lines to multimodality treatment with radiotherapy, temozolomide, and epidermal growth factor receptor inhibition with cetuximab
10.1016/j.ijrobp.2007.03.002 · doi-reference
Integrin-αvβ3 as a therapeutic target in glioblastoma: back to the future?
10.3390/pharmaceutics14051053 · doi-reference
EGFR-based targeted therapy for colorectal cancer—promises and challenges
10.3390/vaccines10040499 · doi-reference
Cellular density effect on RGD ligand internalization in glioblastoma for MRI application
10.1371/journal.pone.0082777 · doi-reference
Stapled RGD peptide enables glioma-targeted drug delivery by overcoming multiple barriers
10.1021/acsami.7b03682 · doi-reference
Application of in vitro transcytosis models to brain targeted biologics
10.1371/journal.pone.0289970 · doi-reference
The hCMEC/D3 cell line as a model of the human blood brain barrier
10.1186/2045-8118-10-16 · doi-reference
Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule
10.1038/309030a0 · doi-reference
RGD modified polymers: biomaterials for stimulated cell adhesion and beyond
10.1016/s0142-9612(03)00343-0 · doi-reference
Human endothelial cell interactions with surface-coupled adhesion peptides on a nonadhesive glass substrate and two polymeric biomaterials
10.1002/jbm.820250209 · doi-reference
Immortalized human cerebral microvascular endothelial cells maintain the properties of primary cells in an in vitro model of immune migration across the blood brain barrier
10.1016/j.jneumeth.2012.10.001 · doi-reference
Modeling and comparison of dissolution profiles
10.1016/s0928-0987(01)00095-1 · doi-reference
Dynamic light scattering and transmission electron microscopy in drug delivery: a roadmap for correct characterization of nanoparticles and interpretation of results
10.1039/d3mh00717k · doi-reference
Antibiotic-loaded amphiphilic chitosan nanoparticles target macrophages and kill an intracellular pathogen
10.1002/smll.202201853 · doi-reference
Applications of chitosan-alginate-based nanoparticles—an up-to-date review
10.3390/nano12020186 · doi-reference
DDSolver: an Add-In program for modeling and comparison of drug dissolution profiles
10.1208/s12248-010-9185-1 · doi-reference
Excipient-free pure drug nanoparticles fabricated by microfluidic hydrodynamic focusing
10.3390/pharmaceutics13040529 · doi-reference
Effect of poly(ethylene glycol) (PEG) spacers on the conformational properties of small peptides: a molecular dynamics study
10.1021/la103800h · doi-reference
Doubly self-assembled dermatan sulfate/chitosan nanoparticles for targeted siRNA delivery in cancer therapy
10.1016/j.jcis.2024.11.132 · doi-reference
Amphiphilic polymeric nanoparticles modified with a protease-resistant peptide shuttle for the delivery of SN-38 in diffuse intrinsic pontine glioma
10.1021/acsanm.0c02888 · doi-reference
Amphiphilic polymeric nanoparticles modified with a retro-enantio peptide shuttle target the brain of mice
10.1021/acs.chemmater.0c01696 · doi-reference
Polyelectrolyte complex coacervates: structural insights, rheological perspectives, and industrial applications
10.1007/s12221-025-00975-4 · doi-reference
Polyelectrolyte complexes: a review of their applicability in drug delivery technology
10.4103/0250-474x.58165 · doi-reference
Ternary polysaccharide complexes: colloidal drug delivery systems stabilized in physiological media
10.1016/j.carbpol.2017.05.051 · doi-reference
Chitosan-based colloidal polyelectrolyte complexes for drug delivery: a review
10.1016/j.carbpol.2020.116126 · doi-reference